scholarly journals Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus

2021 ◽  
Author(s):  
Michael Untch ◽  
Peter A. Fasching ◽  
Sara Y. Brucker ◽  
Wilfried Budach ◽  
Carsten Denkert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Working Group ◽  
Treatment Recommendations ◽  
Consensus Conference ◽  
Current Evidence ◽  
Specific Situation ◽  
Gynäkologische Onkologie ◽  
S3 Guideline ◽  
The Individual

AbstractThis yearʼs 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) with the title “Customizing local and systemic therapies for women with early breast cancer” focused on the challenge of targeting the treatment of early breast cancer more specifically to the individual disease situation of each patient. As in previous years, a German working group of leading breast cancer experts discussed the results of the international SG-BCC 2021 in the context of the German guideline. It is helpful to compare the SG recommendations with the recently updated treatment recommendations of the Breast Commission of the German Working Group on Gynaecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie e. V., AGO) and the S3 guideline because the SG-BCC panel comprised experts from different countries, which is why country-specific aspects can be incorporated into the SG recommendations. The German treatment recommendations of the AGO and the S3 guideline are based on current evidence. Nevertheless, any therapeutic decision must always undergo a risk-benefit analysis for the specific situation and to be discussed with the patient.

scholarly journals Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts’ Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)

Breast Care ◽  
2019 ◽  
Vol 14 (5) ◽  
pp. 315-324 ◽  
Author(s):  
Diana Lüftner ◽  
Ingo Bauerfeind ◽  
Michael Braun ◽  
Sara Y. Brucker ◽  
Peter A. Fasching ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systemic Therapy ◽  
Working Group ◽  
Treatment Decision ◽  
Consensus Conference ◽  
Breast Cancer Patients ◽  
Gynäkologische Onkologie ◽  
S3 Guideline ◽  
Expert Opinions ◽  
Benefit Risk Assessment

A German working group of leading breast cancer experts have discussed the votes at the International St. Gallen Consensus Conference in Vienna for the treatment of primary breast cancer with regard to the German AGO (Ar­beitsgemeinschaft Gynäkologische Onkologie) recommendations for clinical practice in Germany. Three of the German breast cancer experts were also members of this year’s St. Gallen panel. Comparing the St. Gallen recommendations with the annually updated treatment recommendations of the Gynecological Oncology Working Group (AGO Mamma 2019) and the German S3 Guideline is useful, because the recommendations of the St. Gallen panel are based on expert opinions of different countries and disciplines. The focus of this article is on systemic therapy. The motto of this year’s 16th St. Gallen Consensus Conference was “Estimating the magnitude of clinical benefit.” The rationale behind this motto is that, for every treatment decision, a benefit-risk assessment must be taken into consideration for each patient.

scholarly journals Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus

2019 ◽  
Vol 79 (06) ◽  
pp. 591-604 ◽  
Author(s):  
Michael Untch ◽  
Christoph Thomssen ◽  
Ingo Bauerfeind ◽  
Michael Braun ◽  
Sara Y. Brucker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Clinical Practice ◽  
Consensus Conference ◽  
Evidence Based ◽  
Primary Therapy ◽  
Therapeutic Decision ◽  
Everyday Clinical Practice ◽  
S3 Guideline ◽  
Benefit Risk Assessment

AbstractThe results of the international St. Gallen Consensus Conference for the treatment of patients with primary breast cancer were discussed this year by a working group of leading breast cancer experts in view of the therapy recommendations for everyday clinical practice in Germany. Three of the breast cancer experts are also members of this yearʼs St. Gallen panel. The comparison of the St. Gallen recommendations with the annually updated treatment recommendations of the AGO 2019 as well as the S3 guideline is useful, since the recommendations of the St. Gallen panel represent the opinions of experts from various countries and disciplines. The recommendations of the S3 guideline and AGO are based on evidence-based research of the literature. This yearʼs 16th St. Gallen conference featured the motto “Magnitude of clinical benefit”. In addition to the evidence-based data, each therapeutic decision must also undergo a benefit/risk assessment of the patientʼs individual situation and be discussed with the patient.

The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view

2018 ◽  
Vol 172 (3) ◽  
pp. 545-550 ◽  
Author(s):  
Hussein Khaled ◽  
Heba Gamal ◽  
Mohamed Lotayef ◽  
Michael Knauer ◽  
Beat Thürliman
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Consensus Conference ◽  
Expert Consensus ◽  
Primary Therapy ◽  
International Expert

scholarly journals Optimizing Early Breast Cancer Therapies – the 2019 St. Gallen International Breast Cancer Consensus Conference in Vienna

The Breast ◽  
2019 ◽  
Vol 48 ◽  
pp. S1
Author(s):  
Michael Gnant ◽  
Giuseppe Curigliano ◽  
Hansjörg Senn ◽  
Beat Thürlimann
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Consensus Conference ◽  
Cancer Therapies

scholarly journals St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment

Breast Care ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. 103-110 ◽  
Author(s):  
Marija Balic ◽  
Christoph Thomssen ◽  
Rachel Würstlein ◽  
Michael Gnant ◽  
Nadia Harbeck
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Early Breast Cancer ◽  
Patient Empowerment ◽  
Breast Cancer Treatment ◽  
Consensus Conference ◽  
Great Success ◽  
Main Theme ◽  
Treatment Standards ◽  
The Impact

This year, the St. Gallen Consensus Conference on early breast cancer treatment standards took place for the third time in Vienna, Austria, which is where the next conference will also take place (next date: March 17–20, 2021!). Once again, more than 3,000 participants from over 100 countries came together, and, overall, the 2019 St. Gallen/Vienna conference was a great success. After 3 days of reviews conducted by a global faculty concerning the most important evidence published in the last 2 years, the Consensus votes’ challenge was to define the impact on routine everyday practice. This year, the conference’s main theme was the optimization of early breast cancer therapies by assessment of the magnitude of benefit, aiming at further refinement when compared to de-escalation and escalation, which were mainly the topic of the 2017 conference. Patient empowerment and the importance of shared decision-making were particularly emphasized. The traditional panel votes were moderated by Eric Winer from Harvard, and for the most part, they managed to clarify most of the critical questions. This brief report by Editors of Breast Care summarizes the results of the 2019 international panel votes with respect to locoregional and systemic treatment as a quick news update for our readers, but it expressly does not intend to replace the official St. Gallen Consensus publication that will follow shortly in Annals of Oncology.

scholarly journals ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019

2020 ◽  
Vol 80 (06) ◽  
pp. 588-600
Author(s):  
Michael Untch ◽  
Rachel Würstlein ◽  
Diana Lüftner ◽  
Renate Haidinger ◽  
Peter A. Fasching ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Working Group ◽  
Clinical Care ◽  
Breast Disease ◽  
Consensus Conference ◽  
Advanced Breast ◽  
International Consensus ◽  
Study Results ◽  
Patient Advocates

AbstractThe Advanced Breast Cancer Fifth International Consensus Conference (ABC5) which focuses on the diagnosis and treatment of advanced breast cancer was held in Lisbon on November 14 – 16, 2019. The aim of the conference is to standardize the treatment of advanced breast cancer worldwide using evidence-based data and to ensure that patients with advanced breast disease anywhere in the world are treated appropriately and have access to the latest therapies. This year, the emphasis was on new developments and study results from patients with advanced breast cancer as well as precision medicine. The collaboration with patient advocates from all over the globe is also an important goal of the ABC Conference, which is why the international ABC panel also included a number of patient advocates. We present a commentary on the voting results of the ABC5 panelists in Lisbon by a working group of German breast cancer specialists together with the implications for routine clinical care in Germany. The commentary is based on the recommendations of the Breast Commission of the German Gynecological Oncology Working Group (AGO). This commentary is useful, it includes country-specific features for the ABC consensus.

Sign in / Sign up

Export Citation Format

Share Document